HomeProductsBuilding BlocksHeterocyclic ScaffoldsAromatic HeterocyclesDaclatasvir
Chemical structure of CAS 1009119-64-5

Daclatasvir

CAS No.1009119-64-5
MDL No.MFCD17129086
MFC40H50N8O6
MW738.90
InChI KeyFKRSSPOQAMALKA-CUPIEXAXSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Daclatasvir is a biphenyl compound and a potent inhibitor of nonstructural protein 5A, used as its hydrochloride salt in the treatment of hepatitis C. It functions as an antiviral drug and belongs to the classes of imidazoles, carbamate esters, carboxamides, and valine derivatives. It is also a conjugate base of daclatasvir(2+).

CAS No.1009119-64-5
Product NameDaclatasvir

Associated Conditions

COVID-19·hepatitis B virus infection·viral disease·chronic hepatitis C virus infection·severe acute respiratory syndrome·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Characterizations of HCV NS5A replication complex inhibitors.

Virology • Vol. 444, Issue 1-2 • 2013
PMID: 23896639DOI: 10.1016/j.virol.2013.06.032

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

Proceedings of the National Academy of Sciences of the United States of America • Vol. 110, Issue 10 • 2013
PMID: 23431163PMC: PMC3593898DOI: 10.1073/pnas.1203110110

Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.

Bioorganic & medicinal chemistry letters • Vol. 23, Issue 7 • 2013
PMID: 23466233PMC: PMC3602317DOI: 10.1016/j.bmcl.2013.02.023

Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors.

Bioorganic & medicinal chemistry letters • Vol. 22, Issue 10 • 2012
PMID: 22507961PMC: PMC7732024DOI: 10.1016/j.bmcl.2012.03.089

Documentation

Similar Products